{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:21:22Z","timestamp":1754151682040,"version":"3.41.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,19]]},"DOI":"10.7759\/cureus.88333","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T04:37:35Z","timestamp":1752986255000},"source":"Crossref","is-referenced-by-count":0,"title":["Unseen Aggressor: A Case of Amelanotic Melanoma With Orbital Metastasis and Imaging-Pathology Correlation"],"prefix":"10.7759","author":[{"given":"Azalea Guadalupe","family":"Altamirano De La Cruz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar Alberto","family":"Santoyo Reza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Lugo Rinc\u00f3n-Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Ram\u00edrez Saavedra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen Alejandra","family":"Diaz Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.1348","article-title":"Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study","volume":"150","author":"Thomas NE","year":"2014","unstructured":"Thomas NE, Kricker A, Waxweiler WT, et al.. Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. JAMA Dermatol. 2014, 150:1306-314. 10.1001\/jamadermatol.2014.1348","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2248","article-title":"Clinical and dermoscopic characteristics of desmoplastic melanomas","volume":"149","author":"Jaimes N","year":"2013","unstructured":"Jaimes N, Chen L, Dusza SW, et al.. Clinical and dermoscopic characteristics of desmoplastic melanomas. JAMA Dermatol. 2013, 149:413-21. 10.1001\/jamadermatol.2013.2248","journal-title":"JAMA Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2013.03.007","article-title":"Late recurrence in melanoma: clinical implications of lost dormancy","volume":"217","author":"Faries MB","year":"2013","unstructured":"Faries MB, Steen S, Ye X, Sim M, Morton DL. Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg. 2013, 217:27-34; discussion 34-6. 10.1016\/j.jamcollsurg.2013.03.007","journal-title":"J Am Coll Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12368","article-title":"Dermatoscopy of amelanotic and hypomelanotic melanoma","volume":"12","author":"Stojkovic-Filipovic J","year":"2014","unstructured":"Stojkovic-Filipovic J, Kittler H. Dermatoscopy of amelanotic and hypomelanotic melanoma. J Dtsch Dermatol Ges. 2014, 12:467-72. 10.1111\/ddg.12368","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15339","article-title":"Update on dermoscopy of Spitz\/Reed naevi and management guidelines by the International Dermoscopy Society","volume":"177","author":"Lallas A","year":"2017","unstructured":"Lallas A, Apalla Z, Ioannides D, et al.. Update on dermoscopy of Spitz\/Reed naevi and management guidelines by the International Dermoscopy Society. Br J Dermatol. 2017, 177:645-55. 10.1111\/bjd.15339","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter SM","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian CK, et al.. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019, 80:208-50. 10.1016\/j.jaad.2018.08.055","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05928.x","article-title":"Amelanotic\/hypomelanotic melanoma: clinical and dermoscopic features","volume":"150","author":"Pizzichetta MA","year":"2004","unstructured":"Pizzichetta MA, Talamini R, Stanganelli I, et al.. Amelanotic\/hypomelanotic melanoma: clinical and dermoscopic features. Br J Dermatol. 2004, 150:1117-24. 10.1111\/j.1365-2133.2004.05928.x","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert C","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al.. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019, 381:626-36. 10.1056\/NEJMoa1904059","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.0401a09","article-title":"Prediction without pigment: a decision algorithm for non-pigmented skin malignancy","volume":"4","author":"Rosendahl C","year":"2014","unstructured":"Rosendahl C, Cameron A, Tschandl P, Bulinska A, Zalaudek I, Kittler H. Prediction without pigment: a decision algorithm for non-pigmented skin malignancy. Dermatol Pract Concept. 2014, 4:59-66. 10.5826\/dpc.0401a09","journal-title":"Dermatol Pract Concept"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2012-008158","article-title":"'Cannon ball' pulmonary metastases","volume":"2013","author":"Ammannagari N","year":"2013","unstructured":"Ammannagari N, Polu V. 'Cannon ball' pulmonary metastases. BMJ Case Rep. 2013, 2013:10.1136\/bcr-2012-008158","journal-title":"BMJ Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09420-7","article-title":"MRI-based two-stage deep learning model for automatic detection and segmentation of brain metastases","volume":"33","author":"Li R","year":"2023","unstructured":"Li R, Guo Y, Zhao Z, Chen M, Liu X, Gong G, Wang L. MRI-based two-stage deep learning model for automatic detection and segmentation of brain metastases. Eur Radiol. 2023, 33:3521-31. 10.1007\/s00330-023-09420-7","journal-title":"Eur Radiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2021.12.003","article-title":"Immunohistochemistry in melanocytic lesions: updates with a practical review for pathologists","volume":"39","author":"Saleem A","year":"2022","unstructured":"Saleem A, Narala S, Raghavan SS. Immunohistochemistry in melanocytic lesions: updates with a practical review for pathologists. Semin Diagn Pathol. 2022, 39:239-47. 10.1053\/j.semdp.2021.12.003","journal-title":"Semin Diagn Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin JA","year":"2005","unstructured":"Curtin JA, Fridlyand J, Kageshita T, et al.. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005, 353:2135-47. 10.1056\/NEJMoa050092","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long GV","year":"2011","unstructured":"Long GV, Menzies AM, Nagrial AM, et al.. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011, 29:1239-46. 10.1200\/JCO.2010.32.4327","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin J","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019, 381:1535-46. 10.1056\/NEJMoa1910836","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE- 006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert C","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al.. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE- 006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019, 20:1239-1251. 10.1016\/S1470-2045(19)30388-2","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long GV","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, et al.. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017, 28:1631-9. 10.1093\/annonc\/mdx176","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial [published correction appears in","volume":"1016","author":"Dummer R","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al.. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial [published correction appears in. Lancet Oncol. 2018, 1016:1315-27. 10.1016\/S1470-2045(18)30497-2","journal-title":"Lancet Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/386671-unseen-aggressor-a-case-of-amelanotic-melanoma-with-orbital-metastasis-and-imaging-pathology-correlation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T04:37:37Z","timestamp":1752986257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/386671-unseen-aggressor-a-case-of-amelanotic-melanoma-with-orbital-metastasis-and-imaging-pathology-correlation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.88333","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,19]]}}}